Peter Langecker

Biography

Dr. Langecker holds an MD degree and PhD in Medical Sciences from the Ludwig-Maximilians University in Munich, and has extensive experience as practicing clinical oncology and as a drug development scientist in the area of oncology, with experience in planning and implementation of regulatory strategy, FDA and EMA interactions, EMEA and NDA FDA filings and NDA submissions, as well as hands-on experience in in-and out licensing, technology evaluation and strategic portfolio management. He is the holder of several patents in the use of cancer chemotherapy, and most recently has served as the Chief Executive Officer of Oxigene, Inc. for 5 years, and before that as Chief Medical Officer and/or VP Clinical and Regulatory Affairs for several pharmaceutical and biotech companies including Coulter Pharmaceuticals, SUGEN, Intarcia, and Durect. He spent his early career as Medical Monitor at Ciba-Geigy and Schering-Plough in oncology clinical research. He is currently Executive Medical Director, Global Oncology, at Clinipace Worldwide, a digital CRO headquartered in RTP, providing medical consulting services within this global CRO internally and externally: acting as CMO or Medical Monitor, and providing clinical development strategy advice, feasibility assessments, medical monitoring oversight, and business development/public relations for select clients.

Research Interest

Oncology, Pharmaceutical Sciences